COVID-19 Coagulopathy

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Aug 29

PMID 39202695

Authors

Andrew Rettew

Ian Garrahy

Shoja Rahimian

Rebecca Brown

Navdeep Sangha

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease of 2019 (COVID-19) is the respiratory viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite being a primary respiratory illness, it is commonly complicated by systemic involvement of the vasculature leading to arterial and venous thrombosis. In this review, we will focus on the association between COVID-19 and thrombosis. We will highlight the pathophysiology of COVID-19 coagulopathy. The clinical manifestations of COVID-19 vasculopathy will be discussed with a focus on venous and arterial thromboembolic events. COVID-19 vasculopathy and disseminated intravascular coagulation (DIC) are distinguished within, as well as areas of controversy, such as "long COVID". Finally, the current professional guidelines on prevention and treatment of thrombosis associated with SARS-CoV-2 infection will be discussed.

References

Singh B, Aly R, Kaur P, Gupta S, Vasudev R, Virk H . COVID-19 Infection and Arterial Thrombosis: Report of Three Cases. Ann Vasc Surg. 2020; 70:314-317. PMC: 7462876. DOI: 10.1016/j.avsg.2020.08.115. View

Zinellu A, Mangoni A . Serum Complement C3 and C4 and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression. Front Immunol. 2021; 12:696085. PMC: 8215447. DOI: 10.3389/fimmu.2021.696085. View

Nougier C, Benoit R, Simon M, Desmurs-Clavel H, Marcotte G, Argaud L . Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost. 2020; 18(9):2215-2219. PMC: 7405476. DOI: 10.1111/jth.15016. View

Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M . ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020; 18(5):1023-1026. PMC: 9906133. DOI: 10.1111/jth.14810. View

Cheung S, Quiwa J, Pillai A, Onwu C, Tharayil Z, Gupta R . Superior Mesenteric Artery Thrombosis and Acute Intestinal Ischemia as a Consequence of COVID-19 Infection. Am J Case Rep. 2020; 21:e925753. PMC: 7417027. DOI: 10.12659/AJCR.925753. View

Spyropoulos A, Goldin M, Giannis D, Diab W, Wang J, Khanijo S . Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021; 181(12):1612-1620. PMC: 8498934. DOI: 10.1001/jamainternmed.2021.6203. View

Barnes G, Burnett A, Allen A, Ansell J, Blumenstein M, Clark N . Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2022; 54(2):197-210. PMC: 9111941. DOI: 10.1007/s11239-022-02643-3. View

Hanff T, Mohareb A, Giri J, Cohen J, Chirinos J . Thrombosis in COVID-19. Am J Hematol. 2020; 95(12):1578-1589. PMC: 7674272. DOI: 10.1002/ajh.25982. View

Suh Y, Hong H, Ohana M, Bompard F, Revel M, Valle C . Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis. Radiology. 2020; 298(2):E70-E80. PMC: 7745997. DOI: 10.1148/radiol.2020203557. View

10.

Idell S . Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med. 2003; 31(4 Suppl):S213-20. DOI: 10.1097/01.CCM.0000057846.21303.AB. View

11.

Angelini D, Kaatz S, Rosovsky R, Zon R, Pillai S, Robertson W . COVID-19 and venous thromboembolism: A narrative review. Res Pract Thromb Haemost. 2022; 6(2):e12666. PMC: 8847419. DOI: 10.1002/rth2.12666. View

12.

Ramacciotti E, Agati L, Calderaro D, Aguiar V, Spyropoulos A, Carvalho de Oliveira C . Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2021; 399(10319):50-59. PMC: 8673881. DOI: 10.1016/S0140-6736(21)02392-8. View

13.

Kato S, Ishiwata Y, Aoki R, Iwasawa T, Hagiwara E, Ogura T . Imaging of COVID-19: An update of current evidences. Diagn Interv Imaging. 2021; 102(9):493-500. PMC: 8148573. DOI: 10.1016/j.diii.2021.05.006. View

14.

Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart D . Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N Engl J Med. 2020; 383(3):288-290. PMC: 7217555. DOI: 10.1056/NEJMc2013656. View

15.

Subramaniam S, Jurk K, Hobohm L, Jackel S, Saffarzadeh M, Schwierczek K . Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood. 2017; 129(16):2291-2302. PMC: 5399485. DOI: 10.1182/blood-2016-11-749879. View

16.

Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J, Turner A . Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; 126(10):1456-1474. PMC: 7188049. DOI: 10.1161/CIRCRESAHA.120.317015. View

17.

Xu S, Hong V, Sy L, Glenn S, Ryan D, Morrissette K . Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic. Vaccine. 2022; 40(23):3150-3158. PMC: 9013605. DOI: 10.1016/j.vaccine.2022.04.037. View

18.

Santos R, Sampaio W, Alzamora A, Motta-Santos D, Alenina N, Bader M . The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 2018; 98(1):505-553. PMC: 7203574. DOI: 10.1152/physrev.00023.2016. View

19.

Weidemann A, Johnson R . Biology of HIF-1alpha. Cell Death Differ. 2008; 15(4):621-7. DOI: 10.1038/cdd.2008.12. View

20.

Gerber G, Chaturvedi S . How to recognize and manage COVID-19-associated coagulopathy. Hematology Am Soc Hematol Educ Program. 2021; 2021(1):614-620. PMC: 8791093. DOI: 10.1182/hematology.2021000297. View